Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.98.EBIT: As of FY2026 Q1, the actual value is USD -5.084 M.<h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended September 30, 2025, was approximately - $5.1 million, compared to - $4.2 million for the same period in 2024, reflecting a net increase of $900,000.</li><li>Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were approximately $5.3 million, compared to $4.1 million for the same period in 2024, with a net increase of approximately $1.2 million.</li><li>Research and Development Expenses: R&amp;D expenses were approximately $2.9 million for the three months ended September 30, 2025, an increase of approximately $946,000 from $2.0 million for the same period in 2024.</li><li>General and Administrative Expenses: These expenses were approximately $2.3 million for the three months ended September 30, 2025, compared to $2.1 million for the same period in 2024, reflecting a net increase of approximately $216,000.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: Approximately - $3.0 million for the three months ended September 30, 2025.</li><li>Net Cash Provided by Financing Activities: Comprised of net proceeds from capital raise activities totaling $10.5 million.</li></ul><h3>Unique Metrics</h3><ul><li>Clinical Studies: Expenses for clinical studies increased significantly, with the Sunrise PD Phase 2 and Long COVID Program contributing to the rise in R&amp;D expenses.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: BioVie Inc. is focused on advancing its clinical trials for bezisterim (NE3107) in treating Parkinson’s Disease, Alzheimer’s Disease, and Long COVID, with ongoing efforts to secure additional financing to support these initiatives.</li><li>Non-Core Business: The company is targeting a broader ascites patient population for its BIV201 liver disease program, with plans to finalize the protocol design for Phase 3 studies.</li></ul><h3>Priority</h3>BioVie Inc. emphasizes the importance of securing additional financing to continue its operations and advance its clinical programs, highlighting the uncertainty of obtaining sufficient funding on acceptable terms.

BIOVIE INC C/WTS 08/08/2030(TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 0